Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study

Despite intravesical therapy with immunotherapy or chemotherapy intermediate and high risk nonmuscle invasive bladder cancer is associated with a high risk of recurrence and progression to muscle invasive bladder carcinoma.

While intravesical hyperthermia combined with mitomycin C has proved effective to treat nonmuscle invasive bladder cancer, there is less experience with invasive regional 70 MHz hyperthermia and mitomycin C Therefore, we examined the safety and feasibility of this treatment combination for intermediate and high risk nonmuscle invasive bladder cancer

Between 2009 and 2011, 20 patients with intermediate and high risk nonmuscle invasive bladder cancer were treated with intravesical mitomycin C (40 mg) combined with regional hyperthermia Treatment consisted of 6 weekly sessions followed by a maintenance period of 1 year with 1 hyperthermia-mitomycin C session every 3 months Regional hyperthermia was administered using a 70 MHz phased array system with 4 antennas Toxicity was scored using CTC 3 0

The records of 18 of 20 patients could be analyzed Median followup was 46 months Of the 18 patients 15 (83%) completed the induction period of 6 treatments Four patients (22%) discontinued treatment because of physical complaints without exceeding grade 2 toxicity Toxicity scored according to CTC 3 0 was limited to grade 1 in 43% of cases and grade 2 in 14% Mean T90 and T50 bladder temperatures were 40 6C and 41 6C, respectively The 24-month recurrence-free survival rate was 78%

Treatment with regional hyperthermia combined with mitomycin C in patients with intermediate and high risk nonmuscle invasive bladder cancer is feasible with low toxicity and excellent bladder temperatures

The Journal of urology 2015 Jul 02 [Epub ahead of print]

Elisabeth D Geijsen, Theo M de Reijke, Caro C Koning, Paul J Zum Vörde Sive Vörding, Jean J de la Rosette, Coen R Rasch, Rob M van Os, Johannes Crezee

Department of Radiation Oncology and Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands; Department of Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands Electronic address: e d geijsen@amc uva nl , Department of Radiation Oncology and Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands; Department of Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands , Department of Radiation Oncology and Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands; Department of Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands , Department of Radiation Oncology and Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands; Department of Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands , Department of Radiation Oncology and Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands; Department of Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands , Department of Radiation Oncology and Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands; Department of Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands , Department of Radiation Oncology and Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands; Department of Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands , Department of Radiation Oncology and Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands; Department of Urology (TMdR, JJdlR), Academic Medical Center, Amsterdam, The Netherlands

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe